Mainz, Germany, March 7, 2012 – The institute of Translational Oncology (TRON) today officially announced the members of the inaugural TRON Scientific Advisory Board. Five international experts from the fields of immunology and drug development will advise TRON on pursuing new diagnostics and drugs for the treatment of cancer and other diseases of the immune system. TRON’s management is looking forward to working together with these internationally recognized experts, who will support TRON’s mission of translating basic research into the clinic.
The Scientific Advisory Board members are appointed by the TRON Supervisory Board and will serve for two years.
About the TRON Scientific Advisory Board:
Cornelis Melief is Professor Emeritus of Immunohematology at the Leiden University Medical Centre in The Netherlands. Trained as a M.D., he completed his Ph.D. on leukocyte antibodies and immune adherence. His early research focused on T-cell recognition of transplantation antigens. In the past 20 years he has focused mainly on the development of T-cell based immunotherapy against cancer. He is also co-founder and CSO of the biopharmaceutical company ISA Pharmaceuticals. Prof. Melief has published more than 350 articles, several of which were in “Cell” or “Nature” and he is the recipient of the Akzo Nobel Science Award.
Hans Hengartner is Professor Emeritus of Immunology at the Federal Institute of Technology ETH Zurich and University of Zurich. For more than 20 years he directed the Institute of Experimental Immunology together with Prof. Zinkernagel and in January 2000 he became Dean of the Department of Biology at the ETH Zurich. Prof. Hans Hengartner is an expert in immunology and was awarded the Cloëtta Award, the Ernst-Jung-Prize for Medicine and the Otto-Naegeli-Prize for his work on the perforin molecule.
Hartmut Ehrlich is Vice President of Global R&D and Medical Affairs at Baxter BioScience in Vienna, Austria. Prof. Ehrlich has more than 18 years of industry experience in research, development and medical marketing. He has led various clinical development teams and has managed portfolio and product development strategies. Prof. Ehrlich is trained as a physician and medical researcher.
Peter Swetly is Professor and Dean for Research at the University of Veterinary Medicine in Vienna, where he also directs the Biomodels core facility. At the Ernst Boehringer Institute in Vienna he headed the departments for gene technology, biotechnology and immunology. For more than 20 years he was Director for Science and Development at Boehringer Ingelheim Austria (Bender & Co GmbH)
Hansjörg Schild is Professor of Immunology and Managing Director of the Research Center Immunology at Johannes Gutenberg University Mainz. Prof. Schild is an expert in the immunobiology of heat shock proteins, adjuvants and antigen processing and presentation. In 2000 he received the Georges Köhler Award of the German Society for Immunology.